Amritsar-based CDMO exporting generic & biologic formulations to 70+ countries via out-licensing.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 36 | 51 | 171 | 190 | 214 | 254 | 280 | 321 |
| Borrowings | 35 | 41 | 54 | 90 | 98 | 112 | 110 | 130 |
| Other Liabilities | 52 | 64 | 105 | 70 | 72 | 71 | 77 | 130 |
| Total Liabilities | 133 | 166 | 341 | 361 | 394 | 447 | 478 | 592 |
| AssetsFixed Assets | 43 | 57 | 92 | 120 | 139 | 146 | 144 | 156 |
| CWIP | 0 | 3 | 12 | 14 | 0 | 0 | 0 | 17 |
| Investments | 4 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 86 | 102 | 237 | 226 | 255 | 302 | 334 | 420 |
| Total Assets | 133 | 166 | 341 | 361 | 394 | 447 | 478 | 592 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 14 | 6 | 27 | 61 | 41 | 43 | 53 | 17 |
| Cash from Investing | -12 | -18 | -23 | -63 | -48 | -26 | -29 | -35 |
| Cash from Financing | -2 | 12 | 1 | 6 | 1 | -17 | -14 | 7 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 2 | -12 | 3 | 5 | -4 | 17 | 28 | -29 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (22.6×) and current (42.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 70.7% growth and a 23× exit, ₹2782 only delivers your return if you pay ₹11,931. The price is currently baking in 32% growth.
EPS grows 70.7%/yr for 5 years, then fades to 6% over 2, exits at 23×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 70.7% | 110.82 |
| FY28 | 70.7% | 189.17 |
| FY29 | 70.7% | 322.91 |
| FY30 | 70.7% | 551.20 |
| FY31 | 70.7% | 940.91 |
| FY32 | 38.4% ·fade | 1301.74 |
| FY33 | 6.0% ·fade | 1379.85 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.